Ying Ou

机构：BeiGene (China), Natus (United States), Technical Institute of Physics and Chemistry, National Center for Nanoscience and Technology, Hubei Engineering University, University of Chinese Academy of Sciences · ORCID：0000-0003-4169-2325

发表论文 84 篇 · 总被引 1733 次 · h-index 25

代表论文

• Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib (2021 · Expert Review of Clinical Pharmacology · 被引 66)
• Stretchable solvent-free ionic conductor with self-wrinkling microstructures for ultrasensitive strain sensor (2022 · Materials Horizons · 被引 56)
• Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma (2021 · Leukemia & lymphoma/Leukemia and lymphoma · 被引 33)
• A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies (2022 · British Journal of Haematology · 被引 30)
• Emerging conjugated radical polymer cathodes with ultra-long cycle life for an entire polymer rechargeable battery (2022 · Journal of Materials Chemistry A · 被引 25)
• Enhanced magneto-mechano-electric conversion in flexible multiferroic nanocomposites via slender magnetic nanofibers regulated by tailored carbon nanotubes (2022 · Chemical Engineering Journal · 被引 17)